Fujirebio Europe launches the TENDIGO™ instrument for low throughput INNO-LIA® and INNO-LiPA® assay automation

Product news

Gent, Belgium: July 8, 2015 - Fujirebio Europe today announced the release of its new TENDIGO automate. The TENDIGO is a small, state-of-the-art, and cost-efficient instrument designed specifically for laboratories who seek to perform low throughput automation of Fujirebio’s gold standard strip-based INNO-LIA and INNO-LiPA assay portfolios. The instrument also allows for automated testing of other blot strips (open protocols).

“Many general laboratories performing low throughput strip-based assay testing have expressed their wish to move towards more automation and integration of their workflows. These laboratories have typically been looking in vain for accessible solutions to help them take the important first step towards automation” said Christiaan De Wilde, CEO at Fujirebio Europe. “With the TENDIGO automate, which is both an affordable and state-of-the-art instrument, we are confident that we can assist these customers in the crucial evolution of their laboratory organization towards better quality and more efficient testing solutions.”

The TENDIGO instrument further extends Fujirebio’s range of automation solutions for the widely used INNO-LIA and INNO-LiPA assay portfolios. Other automation solutions for these portfolios include the Auto-LIA 48, the Auto-LiPA 48, and the AUTOBLOT 3000(H). The TENDIGO instrument is available worldwide as of today. More information about the TENDIGO can be found here.

Please contact your local sales representative for the availability of these products in your country.

About Fujirebio
Fujirebio is a leading international healthcare company with a strong focus on high quality in vitro diagnostics (IVD) testing solutions. Founded more than 60 years ago in Japan, the company is today recognized as the world-wide market leader in oncology for both routine and novel markers and has a strong reputation in Japan in infectious disease testing in hospitals, clinical labs and blood banks. Over the last 20 years Fujirebio has been committed to bringing solid and successful automated immunoassay testing solutions and state of the art chemiluminescent assay products to the market. Under the name Innogenetics (now Fujirebio Europe) the company has also been pioneering the field of molecular diagnostics and multiparameter testing. The company is today one of the world leaders in strip-based diagnostics solutions.

The product lines range from specialized manual testing to fully automated routine testing and they cover disease fields such as infectious, oncology, genetic testing, thyroid, fertility, tissue typing, neurodegeneration, and bone.

Fujirebio is a subsidiary of Japan-based Miraca Holdings (listed in the Tokyo Stock Exchange - MRCHF) and counts more than 1.100 employees working in Asia, Europe and America, including subsidiaries. For more information about Fujirebio please visit www.fujirebio.com/english.

Veuillez confirmer que vous êtes un professionnel de la santé

Le contenu de ce site web est en partie réservé aux professionnels de santé qui sont directement impliqués dans la fourniture de services de soins de santé aux patients. Si vous êtes un professionnel de santé et que vous disposez de tous les droits d'accès, veuillez confirmer en cliquant sur le bouton 'oui'.

Choose your country or region

Once you have made this selection we will show you only the content that is relevant for your country. You can change this setting any time by clicking on the flag in the top toolbar of our website and choosing another country.
The content of this website is in part restricted to healthcare professionals who are directly involved in the provision of healthcare services to patients. If you are a health professional and you have full access rights, please check this box and confirm below.